All News BioStem Techn. OTC Markets

Equities

BSEM

US0906842002

Market Closed - OTC Markets Other stock markets 03:56:00 2024-04-25 pm EDT			5-day change	1st Jan Change
9.4 ^USD	+0.48%		-4.08%	+60.41%

2023

NovaBay to Commercialize BioStem's Amniotic Tissue Allograft

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioStem Technologies to Present at the 2024 Planet MicroCap Showcase	Apr. 25	AQ
BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior Exchange	Apr. 24	AQ
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference	Apr. 02	AQ
BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase	Apr. 01	AQ
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024	Mar. 21	AQ
PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market	Feb. 26	AQ
Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies	Jan. 30	AQ
BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role	Jan. 11	AQ
BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors	Dec. 19	AQ
Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions	Dec. 14	AQ
BioStem Technologies Bolsters Leadership with Appointment of Thomas Dugan to Board of Directors	Dec. 13	AQ
BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results	Nov. 13	AQ
BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services	Nov. 08	AQ
BioStem Technologies Closes Oversubscribed $2M Private Placement	Nov. 03	AQ
BioStem Technologies to Highlight Core Advanced Wound Care Portfolio at SAWC Fall 2023 Conference	23-10-18	AQ
NovaBay Pharmaceuticals Announces Commercial Launch of Avenova Allograft	23-09-15	AQ
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allograft	23-09-12	AQ
NovaBay to Commercialize BioStem's Amniotic Tissue Allograft	23-09-11	MT
BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell	23-09-06	AQ
BioStem Technologies Commends OIG's Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products	23-03-23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News BioStem Techn. OTC Markets

Equities

BSEM

US0906842002

All News

Filters